News
06-27-2008, 09:20 AM
A breast cancer vaccine currently being tested in a Phase II trial has demonstrated to be safe and well tolerated in patients according to a paper to be published in the Journal of Clinical Oncology. The therapeutic breast cancer vaccine AE37 uses a peptide antigen (immune-stimulating fragment) of a cancer gene known as HER-2/neu. This gene/protein is present in many types of cells, but it is over-expressed in a high proportion of breast cancers as well as many others.
More... (http://www.medicalnewstoday.com/articles/112519.php)
More... (http://www.medicalnewstoday.com/articles/112519.php)